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Abstract
Despite progress in wound treatment including gene therapy, biological dresses and
engineered  skin  equivalents,  present  treatment  options  for  chronic  wounds  are
restricted and not always effective. For example, inability to get consistent product from
the  introduced  gene,  biological  covers  may  give  rise  to  hypoxic  conditions  and
engineered skin models are limited by their construction from substances which are
hard to be degraded, and do not always result in complete replication into normal
uninjured skin. A growing body of evidence suggests mesenchymal stem cells (MSCs),
and their secreted growth factors and microvesicles, may potentiate the wound‐healing
process and as such their addition to novel wound‐healing treatments may improve the
efficacy of  current  therapeutic  strategies.  Recent  studies  report  the  ability  of  bone
marrow‐derived MSCs (BM‐MSCs) to migrate and differentiate into skin cells in vivo.
Therefore, this chapter aims to review the important concepts of wound healing at the
cellular and kinetic level and the potential therapeutic strategies of MSCs through which
to improve their treatment. Focus to this chapter will begin with a description of wound
types, phases of healing process, followed by an outline of the role of MSC secretions
in each phase, leading to potential novel treatment strategies and the requirements for
a successful healing process.
Keywords: cellular therapy, conditioned medium, growth factors, mesenchymal stem
cells, skin regeneration
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1. Introduction
In the United Kingdom, around 200,000 patients experience a chronic wound of varying type,
ranging between ulcerations, scars, trauma and burns. Unfortunately, patient morbidity and
in some cases mortality may result from such injuries for which chronic ulceration is a major
factor [1–3]. One of these impacts is the reduced contribution to society by the individuals
suffering from these chronic wounds including their inability to work [3]. In addition,
healthcare treatment and hospitalisation for chronic wounds are costly [2] involving lengthy
treatment and nursing care. In 2005 and 2006, the care of patients with a chronic wound costs
the UK NHS approximately £2.3bn–£3.1bn each year, with £6.08 million in England lone being
attributed to nursing care [4]. In the United States, approximately 6.5 million patients suffered
from chronic wounds with expenses for wound care management exceeding US $25 billion in
2009 [5]. Furthermore, infection is inevitable, which not only negatively affect wound healing
but can also be life threatening, requiring more hospitalisation and increased healthcare
expenditure [6] and repetitive treatment [7]. Consequently, both the society and the health
sector are negatively affected by the burden of chronic wounds. Moreover, despite great
progress in wound treatment including the implementation of growth factors and biological
engineering of skin equivalents, present treatment options for burns and non‐healing chronic
wounds are restricted and not always effective [8]. Engineered skin to aid the development of
novel wound care strategies is limited by their construction from substances that are hard to
be degraded, and do not always result in complete replication into normal uninjured skin.
Furthermore, complete renewal of this model requires the alteration of immune responses to
reduce fibrotic reactions in order to diminish scar production [9]. Gene therapy may also be
limited by insufficient selection of target cells, the identification of the factors which may affect
the introduction of genes or the inability to produce stable prolonged specific gene product
which is the main problem with systemic gene therapy [10]. Additionally, biofilms give rise to
hypoxic conditions. Therefore, there is an urgent need for new therapies for wounds with
delayed healing [8]. Specific extracellular matrix (ECM) proteins equivalent to the skin, specific
growth factors, mesenchymal stem cells (MSCs), fibroblasts or viable epithelial cells may,
however, aid the wound‐healing process, and their addition to potential wound‐healing
treatments may improve the efficacy of current therapeutic strategies [11]. The availability of
MSCs in normal human skin [12], and their vital function in wound healing suggests that the
exogenous application of such cells may represent a promising solution for the treatment of
non‐healing wounds [13].
Mesenchymal stem cells (MSCs) are generally defined as self‐renewable, multi‐potent pro‐
genitor adult stem cells present in peripheral blood. In vivo, they have the ability to differentiate
widely into many mesenchymal lineages such as cartilage, bone, muscle and adipose tissues
[14]. Furthermore, MSCs have the ability to migrate from the bone marrow to an injured site
and differentiate into functional skin cells [15]. In vitro they can be defined as fibroblast‐like
cells capable of self‐renewal with the ability to adhere to plastic and subsequently differentiate
into adipose, bone, cartilage tissue [16] as well as a multi‐layered epidermis‐like structure [17].
Paracrine factors secreted by MSCs are considered the principle factors with therapeutic
potential for tissue wound healing [18] including growth factors, cytokines and chemokines
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which promote angiogenesis and wound repair [19–22]. Moreover, MSCs produce soluble
factors that regulate cellular responses, angiogenesis formation and tissue remodelling [23]
and play a vital role in each of the five phases of wound‐healing process including haemostasis,
inflammation, proliferation, contraction and remodelling [11]. In addition, MSCs exert
antimicrobial activity via the secretion of the antimicrobial peptide LL‐37 thereby preventing
wound infection [24]. Furthermore, Tamama and Kerpedjieva [25] report that conditioned
medium derived from the cell culture of MSCs (MSC‐CM) contains all the effector molecules
secreted by MSCs which could be effectively utilised in tissue regeneration and wound healing.
Collectively these data thus suggest that MSC‐CM may represent a novel therapeutic strategy
for wound therapy, but the mechanisms mediating these events and exactly how MSCs
contribute in skin regeneration remain undefined.
2. Skin wounds and healing process
Generally, wounds are classified on the basis of location, depth and tissue loss into three
categories: superficial wounds where damage affects the epidermis only; partial thickness
wounds when both the epidermis and dermis are involved; and full thickness wounds which
involve the dermis, subcutaneous fats and sometimes, bones. However, depending on normal
healing trajectory, there are two principal categories of skin wounds: acute and chronic
wounds [26, 27].
2.1. Acute wounds
Acute wounds arise either as a result of surgical incision or following traumatic accidents
including abrasions, superficial burns and partial thickness injuries with significant loss of
tissues. Irrespective to their causes, the healing process of acute wounds is complex and utilises
different types of cells and cytokines [26].
2.2. Chronic skin wounds
Wounds are defined as chronic when they fail to heal during one or all of the phases of the
healing process causing an injury that cannot be repaired within the expected time period of
normal wound repairs [11]. Chronic wounds mainly accompany disorders such as pressure
ulcers, diabetes, burns, vascular insufficiency and vasculitis [5]. The chronic state of non‐
healing wounds is exacerbated by many factors including tissue hypoxia, microbial infection,
necrosis, exudates and an elevated ratio of inflammatory cytokines during the different healing
stages [28]. Neutrophils also contribute by releasing excessive amounts of collagenase which
leads to break down the ECM [29] and enzyme elastase destroying important healing factors
such as PDGF and transforming growth factor‐beta (TGF‐β). Chronic wounds do not respond
to therapeutic methods unless the prolonged inflammation is targeted [11]. Consequently,
human skin with its limited abilities will fail to heal itself in cases of wounds penetrating the
epidermis [30] due to the deficiency in growth factors and cytokines which are depleted during
the healing process [31, 32]
Cellular Therapy for Wounds: Applications of Mesenchymal Stem Cells in Wound Healing
http://dx.doi.org/10.5772/63963
101
2.3. Phases of wound‐healing process
Each wound undergoes a series of successive events for repairing and healing. These processes
take from several minutes such as coagulation, several days such as inflammation to several
months or years such as remodelling and can be divided into three, four or five overlapping
phases and stages. Monaco and Lawrence [26] state the wound‐healing process consists of five
distinct phases: (a) haemostasis, (b) inflammation, (c) cellular migration and proliferation, (d)
protein synthesis and wound contraction and (e) remodelling, while Gosain and DiPietro [33]
and Zhou et al. [34] describe the healing process as consisting of four highly integrated and
overlapping phases: (a) haemostasis, (b) inflammation, (c) proliferation and (d) tissue remod‐
elling or resolution [7]. A normal wound‐healing mechanism is a dynamic and complex process
involving a series of coordinated events, including (a) bleeding and coagulation, (b) acute
inflammation, (c) cell migration, (d) proliferation, (e) differentiation, (f) angiogenesis, re‐
epithelialisation and (g) synthesis and remodelling of ECM. Conversely, Maxson et al. [11]
report that the healing process is a complex event occurring in three overlapping phases: (a)
inflammatory, (b) proliferative and (c) remodelling. These phases and their biophysiological
functions must occur in the proper sequence, at a specific time, and continue for a specific
duration and intensity [35]. There are many factors that can affect wound healing which
interfere with one or more phases in this process, thus causing improper or impaired tissue
repair [28]. All in all, a successful healing process cannot be accomplished without any one of
these processes; haemostasis, inflammation, angiogenesis, proliferation, contraction, re‐
epithelialisation and remodelling [36]. To better understand the healing process, we will
discuss the five phases and how they overlap.
2.3.1. Haemostasis phase (coagulation)
During blood circulation in an intact blood vessel, endothelial cells of the blood vessel secrete
coagulation and aggregation inhibitors, that is they release heparin‐like molecules to prevent
blood coagulation and thrombomodulin to prevent platelet aggregation. Prostacyclin and
nitric oxide are also involved in this process [37]. In contrast, the endothelial cells of broken
blood vessels replace the secretions of clot inhibitors with a blood glycoprotein called von
Willebrand factor (vWF) which initiates haemostasis [37, 38].
Haemostasis is the first phase of wound healing and consists of three successive steps:
vasoconstriction, blockage the wound by platelet aggregation and blood coagulation. When
skin is injured, a blood extravasation begins to fill the injured site. Immediately after the skin
injury and bleeding, the blood vessel contracts and reduces the blood flow to the wounded
site thereby keeping the blood within the damaged vessel and causing bleeding to stop [38,
39]. Not only do vessel contractions stop haemorrhage, but also blood changing from a liquid
phase to a gel phase forming a blood clot (coagulation) and platelet aggregation generates a
haemostatic buffer (plasma) which is rich in fibrin, thereby stopping the haemorrhage and
restoring a barrier protecting the wound from infection by invading microorganisms. This
process constitutes a matrix what encourages cell migration [40, 41]. In this phase, the role of
platelets is not only restricted to blocking the damaged area and in clot formation, but also in
the formation of a transient extracellular matrix by secreting adhesion molecules such as
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fibronectin and thrombospondin, as well as growth factors such as epidermal growth factor
(EGF), platelet‐derived growth factor (PDGF), transforming growth factor‐alpha (TGF‐α) and
beta (TGF‐β), and vascular endothelial growth factor (VEGF) [42]. This matrix serves as a
reservoir for growth factors and cytokines critical to subsequent healing phases [41]. Collec‐
tively, the matrix, activated cascade coagulation and parenchymatous cells make the injured
vessel a chemotactic environment to attract inflammatory cells at the wound site and initiate
the start of inflammatory phase [43].
2.3.2. Inflammation phase
An inflammatory reaction begins soon after the haemorrhage stops at the site of injury. This
reaction promotes mobility of various cells toward the injured tissue giving rise to a multitude
of complicated and successive series of reactions ending with rebuilding of a tissue‐like
structure [44]. The main advantages of this phase are isolating the injured tissues from the
surrounding contaminated environment, cleaning out cell debris and damaged tissues and the
initiation of the healing process [45]. The main reactivity observed in this phase is an increased
migration of inflammatory cells from intravascular tissue towards the extracellular wound site
due to increased vascular permeability. This permeability increases due to vasodilation when
both fibrin and thrombin are activated by the coagulation cascade. Meanwhile, clot formation
and their stimuli are dissipated and plasminogen converted to plasmin [46]. Three main cell
types are involved in the inflammatory phase: neutrophils, macrophages and lymphocytes
whose activity is initiated within hours of injury [44, 45]. Neutrophils seem to be the most
dominant cell type during the first 48 hours, cleaning the wound site from bacteria, cell debris
and damaged tissue by releasing free radicals; however, they are not essential for the healing
process [40, 41, 47]. Approximately 48 hours following the injury, stimuli for neutrophils no
longer persist and neutrophil numbers cease when macrophages (monocyte‐derived macro‐
phage) then penetrate the wound site via the blood and become the dominant cellular
component of the inflammatory phase by phagocytosing cell debris and bacteria including
expended neutrophils. Macrophages also secrete collagenases and elastases to break down the
damaged tissues [48]. In contrast to neutrophils, the role of macrophages is not restricted to
cleaning of the tissues as they also play a crucial role in the healing process by secreting
prostaglandins, which act as vasodilators increasing microvessel permeability and attracting
other inflammatory cells into the wounded site [41, 49, 50]. In addition, macrophages secrete
fibroblast growth factor (FGF), PDGF, TGF‐α and VEGF which are important for proliferation
and migration of fibroblasts as well as cytokines, which attract endothelial cells to the injury
site promoting their proliferation and the development of a new tissue [48, 49, 51]. Within three
days of the inflammatory phase, T lymphocytes home to the injury site by the activity of
interlukin‐1 and secret lymphokines such heparin‐binding epidermal growth factor (HB‐EGF)
and basic fibroblast growth factor (bFGF), promoting fibroblast proliferation [52].
2.3.3. Proliferation phase (epithelialisation)
The proliferation phase (epithelial proliferation phase) represents the main phase responsible
for actual wound closure. In the case of skin wounds, endothelial non‐inflammatory cells such
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as keratinocytes and fibroblasts start to proliferate and migrate towards the edges of the
wound‐producing collagen for the development of new tissues [53–55]. Within a few hours
(between 6 and 24 hours) of injury, TGF‐β and EGF act as mitogenic and chemotactic stimu‐
lators attracting keratinocytes which migrate towards the wound and start epithelialisation
[54]. Fibroblasts are activated and start to differentiate into myofibroblasts which participate
in reducing the wound size by contracting and secreting extracellular matrix (ECM) proteins
giving rise to healing of the connective tissue [56, 57]. Meanwhile, angiogenesis progresses,
coordinating the transfer of nutrients and oxygen from newly formed capillaries to the wound
site enhancing metabolic activity [58]. Epithelisation, fibroplasia and angiogenesis collectively
comprise granulation tissue which covers the damaged tissues within four days of injury [55].
2.3.4. Contraction phase
Wound contraction could be defined as mobility of wound margins towards the wound core
to facilitate closure; this phase begins when fibroblasts stop proliferating and undergo
apoptosis within 5–15 days post‐injury which occurs concurrently with collagen synthesis [59,
60]. The rate of movement of wound edges depends on tissue laxity and wound shape; for
instance, the looser tissues tend to contract more rapidly than the compact tissues and squared
wounds contract more quickly than rounded wounds. The contraction rate also depends on
the availability of myofibroblast and their proliferation and connection to the surrounding
extracellular matrix [61].
2.3.5. Remodelling phase (resolution)
Remodelling or resolution is the last phase of the wound‐healing process. The biological
processes observed in this step involve gradual resolution of the inflammatory phase, collagen
deposition, complete coverage of the injured site by the new tissues and formation of scar
tissue [62]. Successful remodelling requires stable collagen content; therefore, the important
step in this phase is controlling collagen remodelling [34]. Although collagen synthesis is
continuing during this phase, its level is restricted due to the activity of collagenases and
metalloproteinases which aid in removing the excess collagen [63, 64]. For optimal remodel‐
ling, collagen levels need to be balanced by the activity of metalloproteinases inhibitors
secreted by tissue arresting the collagenolytic enzymes and balancing the production of new
collagen with that of the removed old collagen [64]. The outcome of this process is that collagen
type III is replaced by collagen type I, hence replacing both hyaluronic acid and glycosami‐
noglycans by proteoglycans and the disappearance of fibronectin as well as resorbing water
from scar tissues. These events start approximately 3 weeks after the injury and may last
indefinitely as collagen fibres stack closer to each other decreasing scar thickness and increas‐
ing wound bursting strength ‘resistance to rupture’ [65].
As described above, the main issues in the wound‐healing process are how cells are attracted
to the site of injury site and how to enhance their proliferation and differentiate at the wounded
region. These cells include inflammatory cells (neutrophils, macrophages and lymphocytes)
and epithelial cells (fibroblasts and keratinocytes). All these activities are mainly regulated by
growth factors and cytokines. In many cases, these cells fail to migrate, proliferate and
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differentiate due to deficiency in growth factors and cytokines; consequently, the healing
process will be impaired and chronic wounds will arise [54]. Therefore, in order to improve
wound healing, there is a need for an alternative source of healing cytokines and growth factors
to enrich the injury site. MSC‐CM acts as a rich source of 36 growth factors, cytokines and
chemokines which collected from MSC in vitro under good manufacturing practice could be
used as therapy for wounds in the future [66]. The main events and phases of the wound‐
healing process are summarised in Table 1.
Phase Haemostasis Inflammation Proliferation
migration
Contraction Remodelling
Starts
post‐
injury
Immediately First hours Day 4 Day 5 Day 20
Duration (minutes–hour) (3 days to 14 days) (21 days) (10 days to 20
days)
(Months to 2 years)
Events
Haemorrhage Phagocytosis Endothelial cells
migration
Fibroblast
apoptosis
Collagen control
remodelling
Vasoconstriction Growth factors secretion Epithelialisation Wound edges
pull
Replacing collagen
type III by type I
Platelet
aggregation 
Cytokines secretion Fibroblast
differentiate into
myofibroblasts
Wound closure Disappearance of
fibronectin
Blood coagulation Synthesis of preliminary
ECM
ECM production Scar maturation
Immunomodulation by
T lymphocytes
Angiogenesis Collagen fibre cross‐linking
Migration of inflammatory cells Collagen production
Activation of coagulation cascade Granulation
Fibroblast migration
Fibroplasia
Healing
progress
(a) Wound
initiated
(b) Healing
not initiated
(c) Progressive
healing
(d) Healed (e) Healing
complete
This table shows the main phases and events of the wound‐healing process which are divided into five overlapping
phases. For example, the phase (a) indicates that the wound is not healed and there is a possibility to reach a chronic state
if the coagulation phase failed. The phase (b) indicates that the wound is still not healed, but it is progressing towards
healing; however, if the inflammation is not terminated, a chronic condition has a chance to be initiated. The phase (c)
indicates that the active healing process has been initiated. The phase (d) represents further development of the healing
process with less chance of progression to a chronic condition. The phase (e) represents the complete healing and
remodelling.
Table 1. The main phases and events of the wound‐healing process.
Cellular Therapy for Wounds: Applications of Mesenchymal Stem Cells in Wound Healing
http://dx.doi.org/10.5772/63963
105
3. Utilisation of mesenchymal stem cells in wound healing
3.1. Definition of mesenchymal stem cells
MSCs can be defined as a heterogeneous population of cells which are non‐hematopoietic stem
cells with the potential capacity to differentiate into various somatic lineages and tissues of
both mesenchymal and non‐mesenchymal origin [67]. Song et al. [68] have defined MSCs as a
type of stem cell population capable of self‐renewing and differentiating into different cell
types with pluripotent potential. On the other hand, MSCs have also been termed marrow
stromal cells, or fibroblastoid colony‐forming unit (FCFU) [69], mesenchymal stem cells,
multipotent mesenchymal stromal cells or stromal progenitor cells [23]. MSCs can be isolated
from different tissues; however, they share the major criteria defining MSCs with minor
differences related to their differentiation capacity and cell surface expression profile [67, 70].
These differences have challenged the definition of MSCs. In 2006, the International Society
for Cellular Therapy (ISCT) attempted to demystify the nomenclature of MSCs suggesting that
the term mesenchymal stem cells should only be referred to the cells which are characterised
by the specific criteria, while the nomenclature of multipotent mesenchymal stromal cells
should be used to describe the fibroblast‐like plastic‐adherent population irrespective of their
source of origin [16, 23, 71]. Three minimal criteria have been agreed to become consensus
characteristics shared by human MSCs [16, 23, 72, 73]. These criteria are:
1. The isolated MSCs should possess plastic adherence ability.
2. More than 95 % of the isolated MSCs must express CD73 (SH3), CD90 and CD105 (HS2),
and more than 98 % of the isolated MSCs do not express CD14, D19, CD34, CD45, CD11b,
CD79a and HLA‐DR surface molecules.
3. The isolated MSCs have the capacity to differentiate into osteoblastic, chondrogenic and
adipogenic lineages under in vitro standard differentiation conditions.
3.2. Clinical applications of mesenchymal stem cells
MSCs have been considered as safe irrespective to therapeutics since there is no critical inverse
or side effect of MSCs has been detected on disease conditions [74, 75]. The characteristics of
MSCs make them good candidates for regenerative medicine and tissue engineering [8, 25].
The most popular application of MSCs in regenerative medicine is in wound healing and skin
regeneration [76]. However, MSCs have other clinical applications including ameliorating
tissue damage in nearly all the major organs in the body such as skin regeneration, cardiac
therapy, hepatic cirrhosis [23, 77, 78], brain, lung and kidney repair [23, 77]. In addition, MSCs
can be used for pancreatic regeneration, neurological defects, limb ischemia, graft‐versus‐host
disease (GvHD), rheumatoid arthritis, osteoarthritis (OA) and other bone and cartilage
disorders [78]. The availability of MSCs in normal human skin suggests that these cells
potentiate vital functions in wound healing and could be a promising solution for the treatment
of chronic wounds [8, 25].
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3.3. Mesenchymal stem cells in skin regeneration
Wounding in mammals evokes two types of biological responses: tissue regeneration and
wound repair. Recently, skin regeneration especially cutaneous regeneration via MSCs leads
to accelerated wound closure, re‐epithelialisation and angiogenesis [7]. BM‐MSCs
transplanted into the injury site expressing keratinocyte‐specific protein (KSP) form glandular
structures [79, 80]. One of these successful studies is the induction of BM‐MSCs to acquire
phenotypic characteristics of sweat gland cells (SGCs) in vitro followed by re‐transplantation
of these cells into fresh wounds in five patients and resulted in recovery of functional sweat
gland participating in perspiration function during 2 to 12 months follow‐up [81]. Another
study focusing on chronic diabetic foot ulcers showed that injection of a biografts consisting
of a combination of MSCs and autologous skin fibroblasts resulted in increase of both dermal
thickness and vascularity and decreased wound size [82, 83]. Another study has showed that
MSCs acquire phenotypic characteristics of epidermal cells or vascular endothelial cells after
in vitro culture in media supplemented with EGF or VEGF, respectively [82]. MSCs also
undergo trans‐differentiation into keratinocytes enabling them to interact with the original
epidermal cells suggesting that MSCs can participate directly in tissue regeneration of both
dermal and epidermal cells [30]. These characteristics, collectively, reveal the plasticity of MSCs
and suggesting them promising therapeutic for the regeneration of skin and consequently
wound healing [81].
3.4. Modes of action of mesenchymal stem cells in wound healing
The wound‐healing process requires interaction between cells, extracellular matrix proteins
(EMP) and biomolecules such as growth factors, cytokines and chemokines in which MSCs
are a pivotal player in the coordination of the repair processes [11, 84]. Differentiation and
Figure 1. Potential applications of MSCs in wound healing. MSC therapy contributes to skin wound healing via two
mechanisms: (1) Differentiation into skin‐like cells, thereby compensating for the loss cells due to damaged tissue. (2)
Promote proliferation and migration of skin cells into the injury site by secreting soluble factors and macrovesicles.
MSC secretions represented by MSC‐CM and MSC‐EXOSOME can be either injected onto the wounded skin area or
applied on skin wound using biofilm dressings.
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paracrine signalling have both been implicated as mechanisms by which MSCs recruit other
host cells in all steps of healing process to improve tissue repair [23]. To better understand the
role of MSCs in wound healing, we have divided their participation in repair into two major
mechanisms: (1) cell‐mediated repair and (2) secretory‐mediated repair (Figure 1).
3.4.1. Cell‐mediated repair
In vitro studies have shown that MSCs possess phenotypic properties resembling native dermal
fibroblasts or myoblasts [85]. Furthermore, BM‐MSCs may accelerate wound closure by
differentiating into epidermal keratinocytes and other skin cells [15, 23, 79, 86, 87]. Recent
studies have shown that MSCs undergo trans‐differentiation into keratinocyte, epidermal cells
and microvascular endothelial cells when cultured under defined culture conditions [30] and
express keratinocyte‐specific protein (KSP) [79, 88, 89]. MSCs therefore could be utilised for
wound healing by transplanting aggregated MSCs into the injured tissue to increase collagen
deposition and improve epithelisation [80]. They can also differentiate into other skin cells
such as endothelial cells, keratin 14‐positive cells and pericytes, when localised to blood vessels
and dermis [86], sebaceous glands and hair follicles [23].
3.4.2. Secretory‐mediated repair–role of mesenchymal stem cell‐conditioned media (MSC‐CM)
Paracrine signalling of BM‐MSCs is the major mechanism by which these cells contribute to
wound repair, in which their secretory products impact on inflammation, fibrotic proliferation
and angiogenesis [18]. Many studies have reported that MSC‐CM is the supernatant from MSC
in vitro culture significantly promotes wound healing by affecting the pivotal steps of the repair
process. The components of MSC‐CM have accelerated epithelialisation and via chemotaxis
recruit endothelial cells and macrophages to the injured site in vivo [21]. The MSC‐CM recruits
both epidermal keratinocytes and dermal fibroblasts to the wound site in vitro [21, 23]. As well
as to its activity as chemoattractant, MSC paracrine secretions serve as regulators for cell
migration in response to wounding leading to faster wound closure by regulating dermal
fibroblast migration [90]. MSC secretory mitogenic molecules stimulate the proliferation of
keratinocytes, dermal fibroblasts and endothelial cells [91]. Conditioned medium derived from
the cell culture of MSCs (MSC‐CM) contains all the effector biomolecules which could be
effectively utilised in tissue regeneration and wound healing by promoting migration,
proliferation and differentiation of human skin cells such as fibroblast and keratinocytes.
Collectively, these data suggest MSC‐CM may represent a novel therapeutic strategy for
wound therapy [25].
3.5. Biologically active substances secreted by mesenchymal stem cells
The potential of MSCs in regenerative medicine and wound healing has been reflected by their
secretion of biomolecules including growth factors, cytokines and chemokines [18, 21, 25].
Some 36 biomolecules have been reported to be released by human MSCs (h‐MSCs) which act
in concert to promote the wound‐healing process [66].
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3.5.1. Growth factors
Human MSCs secrete a wide range of growth factors that play a significant role in the wound‐
healing process. These are angiopoietins (ANGPT), connective tissue growth factors (CTGFs),
epidermal growth factor (EGF), fibroblast growth factors (FGFs), insulin‐like growth factors
(IGF), keratinocyte growth factor (KGF), nerve growth factor (NGF), platelet‐derived growth
factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF)
and scatter factors which are a family of growth factors also known as plasminogen‐related
growth factors (PRGFs), which include two members: hepatocyte growth factor (HGF) also
referred to as plasminogen‐related growth factor‐1 (PRGF‐1) and macrophage‐stimulating
protein (MSP) which is also known as scatter factor‐2 (SF‐2) or hepatocyte growth factor‐like
protein (HGFL) (Table 2).
Growth
factors
Function(s) References
ANGPT ANGPT‐1 is responsible for the stabilisation of blood vessels and promotes wound
closure   
[21, 22]
ANGPT‐2 causes vessel destabilisation and remodelling    [40]
CTGFs Stimulation of chemotaxis, proliferation of fibroblasts and the induction of extracellular
matrix proteins including fibronectin and collagen type I   
[40]
Promote endothelial angiogenesis, survival, migration, proliferation and adhesion    [92]
EGF Re‐epithelialisation of skin wounds and    [40]
promotion of wound closure    [22]
FGFs Exert a cytoprotective function in would repair, supporting cell survival under stress
conditions   
[93]
Promotes mitogenic activity for keratinocytes and fibroblasts at the wound site. FGF1 and
FGF2 stimulate angiogenesis. Basic fibroblast growth factor (bFGF) enhances the
proliferation of endothelial cells and smooth muscle cells   
[94]
IGF In association with HB‐EGF, IGF enhances the proliferation of keratinocyte in vitro.
Mitogenesis and survival of many cells are stimulated by IGF‐I and IGF‐II, promotes
wound closure   
[40]
KGF Promotes wound closure in two ways:    [21, 22]
(1) It serves as a transporter for alveolar epithelial fluid    [94]
(2) It plays a role in tissue remodelling    [11]
NGF Involved in fibroblast migration, increasing expression of actin by smooth muscle and
collagen gel contraction by these cells   
[95]
Performs two functions in wound healing: (1) it stimulates proliferation of keratinocytes
and inhibits apoptosis in vitro, (2) it supports the proliferation of human dermal
[40]
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Growth
factors
Function(s) References
microvascular endothelial cells and their adherence molecule expression   
PDGF Stimulates DNA synthesis, attracts fibroblasts to wound sites, enhances their production of
collagenase, collagen and glycosaminoglycan   
[96]
The first chemotactic growth factor participating in migration of fibroblasts, monocytes and
neutrophils into the skin wound, subsequently stimulating the production of extracellular
matrix and the induction of a myofibroblast phenotype   
[97]
HGF or
PRGF‐
1   
It inhibits fibrosis and promotes re‐epithelialisation [98]
Enhances keratinocytes to migrate, proliferate and produce matrix metalloproteinase and
stimulates new blood vessel formation   
[99]
MSP Accelerates cell migration and proliferation with regulation of proliferation and
differentiation of keratinocytes and macrophages. plays an integral role in inflammation,
proliferation and the remodelling phases of the healing process   
[40, 100]
TGF Enhances proliferation of epithelial cells, expression of antimicrobial peptides
and release of chemotactic cytokines   
[40]
TGF‐β1 activates keratinocytes and macrophages, while suppressing T lymphocytes    [94]
TGF‐β3 stimulates remodelling [11]
Activins which are members of TGF‐β family act as enhancers for granulation tissue
fibroblasts and the induction of extracellular matrix deposition   
[40]
Activin B supports wound repair and regeneration of hair follicles, promotes wound
closure   
[21, 22]
VEGF Regulates angiogenesis    [20, 40]
VEGF‐α promotes wound closure    [21, 22]
Promotes proliferation of endothelial cells    [11]
MSCs secrete a wide spectrum of growth factors. These biological substances participate in wound healing from early
stages starting with haemostasis and coagulation and ending with remodelling. These growth factors promote
angiogenesis, accelerate proliferation and also migration of endothelial cells. In addition, they are involved in the
contraction phase, ending at the last stages of remodelling, leading to wound healing in the absence of scar formation.
Table 2. The main growth factors secreted by MSCs and their roles and functions in the wound‐healing process.
3.5.2. Cytokines
Cytokines are small proteins secreted by many cell types which affect the activity of other cells
including immune cells; they include interleukins, lymphokines and other signalling biomo‐
lecules including interferons and tumour necrosis factor [40]. Here, they are categorised into
groups depending on their role in the wound‐healing process (Table 3).
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Cytokines Function(s) References
Pro‐inflammatory cytokines
IL‐1α
IL‐1β
IL‐6
TNF‐β
They influence the inflammatory phase [101–103]
They promote wound healing by controlling the proliferation
of fibroblast and keratinocyte and regulate the synthesis and breakdown of extracellular
matrix proteins. They also control fibroblast chemotaxis and regulate the immune response
[40]
Anti‐inflammatory cytokines
PGE2
IL‐1
IL‐4
They play a primary role in limitation and termination of inflammatory responses [11, 40, 102–106]
LL‐37 It acts as antimicrobial peptide and reduce inflammation [24]
Proliferative cytokines
IL‐6 Plays an axial role in wound healing by regulating cellular responses [8, 23]
Promotes epithelial cell migration [25]
Promotes angiogenesis formation [8, 25, 107]
Regulates leukocyte recruitment and infiltration to the
inflammatory sites and regulates collagen deposition
[107]
Possess both pro‐inflammatory and anti‐inflammatory activities under different conditions
of the wound‐healing process
[25, 105]
IL‐10 Regulates differentiation and/or growth of keratinocytes, endothelial and various immune
cells
[108]
Regulates the infiltration of macrophage‐derived neutrophils into the wound site, promotes
the expression of pro‐inflammatory cytokines and reduces matrix deposition and thereby
inhibiting scar formation
[40]
GM‐CSF Enhances wound healing either indirectly via stimulating secondary cytokines such as
TGF‐β1
[109]
Directly via its mitogenic activity for keratinocytes, and the
stimulation of endothelial cell proliferation and migration
[40]
Regulating angiogenesis formation, cellular responses and tissue remodelling [8]
MSCs secrete a wide range of cytokines. These secretions initiate and terminate the inflammatory phase and accelerate
proliferation and also migration of endothelial cells. In addition, they are involved in the contraction phase, ending at
the last stages of remodelling, leading to wound healing in the absence of scar formation.
Table 3. The main cytokines secreted by MSCs and their roles and functions in the wound‐healing process.
3.5.3. Chemokines
Chemokines are a subtype of small cytokines responsible for stimulating chemotaxis and
extravasation of leukocytes; hence, referred to as so, they are called chemotactic cytokines [40].
Human MSCs release several chemokines that participate in wound healing such as IL‐8 and
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its receptor (CXCL8), macrophage chemoattractant protein‐1 (MCP‐1) and its receptor (CCL2),
macrophage inflammatory protein‐1‐alpha and macrophage inflammatory protein‐1‐beta
(MIP‐1α and MIP‐1β) and stromal‐derived factor 1 (SDF‐1) (Table 4).
Chemokines  Function(s) References
IL‐8 Increases keratinocyte proliferation and stimulate re‐epithelialisation in human
skin grafts, both in vitro and in vivo. IL‐8 and its receptor
(CXCL8) act as a chemoattractant
for neutrophils
[110]
Enhances the migration of epithelial cells in vitro [25, 111]
MCP‐1 MCP‐1 and its receptor (CCL2) are primarily involved in macrophage infiltration [66, 105]
Inflammation regulatory chemokines in the wound‐healing process [40]
MIP‐1 MIP‐1α and MIP‐1β promote wound closure [21, 22]
MIP‐1α and MIP‐1β increase macrophage trafficking [105]
SDF‐1 Plays a role in regulating skin homeostasis and tissue remodelling [40]
Promotes wound closure [21, 22]
Induces cell migration [74]
MSCs secrete some chemokines. These biological substances participate in wound healing from early stages starting with
haemostasis and coagulation and ending with remodelling. They also participate in the inflammatory phase and
accelerate proliferation and also migration of endothelial cells. In addition, they are involved in the contraction phase,
ending at the last stages of remodelling, leading to wound healing in the absence of scar formation.
Table 4. The main chemokines secreted by MSCs and their roles and functions in the wound‐healing process.
3.5.4. Mesenchymal stem cell exosomes (MSC‐EXOSOME)
Exosomes are tiny vesicles (30–100 nm in diameter) present in blood and urine and perhaps
all other biological fluids that may also be collected from in vitro cell culture [112, 113].
Originating from endosomal sections and released from the plasma membrane into the
extracellular environment these vesicles participate in coagulation, intracellular communica‐
tion and signalling and cytoplasmic cleaning [112–115]. It has been reported that MSC‐
EXOSOME repair renal injury indicating that MSC‐EXOSOME as a potential mechanism that
could be harnessed for wound healing [116, 117]. With respect to wound healing, MSC‐
EXOSOME plays an important role in collagen synthesis, the acceleration of cell migration and
proliferation and in the formation of new and mature blood vessel [113]. Exosome healing
action could be attributed to its ability to transfer RNA, miRNA and proteins such as Wint‐4
into the injured tissues which participate in skin repair by promoting re‐epithelialisation and
cell proliferation as well as through the activation of β‐catenin which plays a pivotal role in
skin development and wound healing [116]. Additionally, MSC‐EXOSOME has been shown
to accelerate wound healing through mediating pathway signalling of some genes such as Akt,
ERK and STAT3 as well as by enhancing the expression of important growth factors, Such as;
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HGF, IGF‐1, NGF and SDF‐1 which collectively accelerate migration and proliferation of
fibroblasts in normal and diabetic wounds [118]. Moreover, MSC‐EXOSOME reduces levels of
pro‐apoptotic Bax thereby inhibiting apoptosis of skin cells such keratinocytes and fibroblasts
[117, 119]. Collectively, these data suggest the MSC‐EXOSOMES thus play a significant role in
wound healing.
The application of MSC‐CM or MSC‐EXOSOME onto chronic wounds either by direct injection
or by designing biological dressings enriched with MSC‐CM collected from autologous MSCs
may therefore provide a valuable therapeutic strategy.
The participation of MSC secretions in wound healing is summarised in Figure 2.
Figure 2. Participation of MSC secretions in wound‐healing phases and events. MSCs secrete a wide spectrum of
growth factors, cytokines and chemokines. These biological substances participate in wound healing from early stages
starting with haemostasis and coagulation and ending with remodelling. These secretions initiate and terminate the
inflammatory phase and promote angiogenesis, accelerate proliferation and also migration of endothelial cells. In addi‐
tion, they are involved in the contraction phase, ending at the last stages of remodelling, leading to wound healing in
the absence of scar formation.
3.6. Benefits of the use of mesenchymal stem cells in treating wounds
As we previously mentioned, MSCs have been considered safe irrespective their use in
different clinical indications, since no critical adverse or side effect of MSCs has been shown
when used therapeutically in humans [74, 75, 120]. Interestingly, patients with conditions such
as sepsis [106], acute limb ischemia, acute GvHD [78, 120], critical myocardial infarction,
Crohn’s disease, acute tubular necrosis and multiple sclerosis can obtain benefit from the use
of MSC therapies with no reported contraindications [120].
3.6.1. Immunomodulatory features of MSCs
In 2000, Liechty et al. [121] were the first to recognise that MSCs possess unique immunologic
features allowing them to persist in a xenogeneic environment and modulate the immune
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response. They have the potential to reduce inflammation and enhance repair wounds [122].
The exact mechanism by which MSCs modulate the immune system is not fully understood.
The potential mechanism includes cell‐to‐cell direct contact and by the secretion of immune
suppressive factors, interacting with other immune cells such as T lymphocytes, B lympho‐
cytes, dendritic cells (DC) and natural killer cells (NKCs) [123]. In 2013, Patel et al. [74] reported
that MSCs suppress both the activation and proliferation of lymphocytes in response to
allogeneic antigens as well as enhancing the development of CD8+ regulatory T cells (Treg) in
the suppression of an allogeneic lymphocyte response. Additional immune suppressive
activities of MSC include inhibition of differentiation of peripheral blood monocyte progenitor
cells and CD34+ haematopoietic progenitor cells (HPCs) into antigen‐presenting cells (APCs)
[124]. MSCs also inhibit the proliferation of NK cells mediated by IL‐2 or IL‐15 [125]. MSCs
have been shown to exert other immunomodulatory activities including altering the prolifer‐
ation and activation of B cells, IgG production, antibody secretion, chemoattractant behaviour,
and reducing the expression of CD40, and CD86 and major histocompatibility complex class
II (MHC‐II) [126].
The ability of MSCs to modulate T cell and their proliferation, participation and activity [127]
and suppress the proliferation of B cells [128] and NK cells [125] is well documented. By
attenuating the function of these cells, MSCs reduce the pro‐fibrotic process [129]. Importantly,
by the secretion of Prostaglandin E2 (PGE2) [102, 103] and 1L‐10 [11, 40, 106], MSCs regulate
macrophage and lymphocyte function [30]. For instance, PGE2 attenuates mitogenesis and
proliferation of T cells in the wound [124] acting as co‐parameter in regulating the transition
from Th1 cells into Th2 cells [130]. On the other hand, IL‐10 prevents the deposition of excessive
collagen and inhibits the invasion of neutrophils into the wound and their release of reactive
oxygen species (ROS) factors, which collectively participate in the prevention of scar tissue
formation [30].
3.6.2. Migration and engraftment capacity
Various studies have reported the capability of MSCs to selectively migrate to and engraft into
the wound site and exert local functional effects on inflammatory reactions regardless of tissue
type [30, 73]. In this context, murine studies have shown that MSCs can home to the lung,
adopting phenotypic characteristics of epithelium‐like cells and reducing inflammation in
response to injury [131]. Another study in mdx mice, a strain of mice arising from a
spontaneous mutation (mdx) in inbred C57BL mice showed that MSCs may migrate to muscle
tissues [132]. MSC migration has been shown to be regulated by a multitude of signals [133]
ranging from growth factors such as PDGF and IGF‐1, cytokine such as SDF‐1, chemokine such
as CCL5 and chemokine receptors, including CCR2, CCR3 and CCR4 [73, 134].
3.6.3. Wound closure acceleration
MSCs play a role not only in wound healing but also in accelerating the healing process by
increasing the strength of wound and by reducing scaring [23]. The effects of MSCs during
wound healing include acceleration of epithelialisation, an increase in angiogenesis and the
formation of granulation tissue [11]. These activities are attributed to the ability of MSCs to
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produce biologically active substances capable of accelerating the regeneration process [135]
including IL‐8 and CXCL1, responsible for stimulating the migration of epithelial cells and
accelerating wound closure [111].
3.6.4. Antimicrobial activity
Conditioned medium of hBM‐MSCs is capable of inhibiting bacterial growth directly indicat‐
ing the ability of MSCs to produce and release substantial amounts of antibacterial substances
known as human cathelicidin peptide‐18 (hCAP‐18) or LL‐37 peptide which are characterised
by their ability to retard in vitro growth of Pseudomonas aeruginosa and Escherichia coli [24], thus
avoiding wound contamination and infections complications which exacerbate the healing
process [28].
3.6.5. Prevent chronic condition
Besides having immune modulatory activities, the effective biomolecules secreted by MSCs
can prevent wounds from reaching a chronic state by their angiogenic and antiapoptotic
characteristics [105]. For instance, transplantation of hMSCs intramyocardially has the ability
to improve cardiac function via enhancing myogenesis and angiogenesis in the ischemic
myocardium [136]. Also, MSCs enable a wound to progress to healing beyond the inflamma‐
tion stage and not regress into a chronic state [11].
3.6.6. Attenuation of scar formation
The tissues in the scar have many disadvantages including their undesirable visual appearance
and lack of structures that are present in the native skin such as hair follicles, sebaceous glands
and sensory nerve receptors [30]. In addition, scar tissue weakens the skin making it more
susceptible for re‐injury [137]. MSCs have been shown to overcome these disadvantages via
attenuating scar formation [138].
3.6.7. Neutralising the reactive oxygen species (ROS)
Although IL‐10 participates in preventing the invasion of neutrophils into the site of tissue
injury and the enhancement of collagen deposition, the penetrations of some populations result
in the release of ROS, which are oxygen molecules have an unpaired electron making them
extremely reactive such as superoxide, hydrogen peroxide and alkyl peroxides [139]. Many
tissues are susceptible to attack by ROS contributing to dangerous diseases including heart
disease and cancer. Also, prolonged persistence of ROS induces fibrogenesis and the accumu‐
lation of fibrotic tissues [30]. To counter act such effects, MSCs significantly upregulate the
expression of nitric oxide synthase [140] which alters the ROS balance preventing the formation
of fibrotic tissues [141].
3.6.8. Producing antifibrotic factors
MSCs release growth factors and cytokines characterised by their antifibrotic activities such
as HGF and IL‐10 [142]. HGF has been shown to downregulate the expression of collagen type
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I and type III by fibroblasts therefore attenuating fibrosis and scar formation [143]. Moreover,
HGF impacts on the keratinocyte behaviour by promoting their migration, proliferation and
expression of VEGF‐A, thereby generating a well‐granulated tissue with a high degree of
vascularisation and re‐epithelialisation [30].
3.6.9. Enhancing dermal fibroblast function
In response to the wounding process, fibroblasts present at the injury site produce additional
quantities of ECM to restore the integrity of the skin leading to scarred tissue [144]. Also, many
endothelial cells undergo epithelial‐to‐mesenchymal transition (EMT) under the effect of TGF‐
β1 and become wound‐healing myofibroblasts [138]. Both of these actions affect the function
of dermal fibroblasts. Therefore, MSCs present in the wound site enhance dermal fibroblast
function by producing HGF and PGE2 which both play a role in inhibiting EMT [145] and
secrete biomolecules promoting the function of dermal fibroblast in wound healing [90]. MSCs
therefore enable the cells present in the wound site to release ECM similar to those produced
by neighbouring dermal cells [30].
3.6.10. Promoting angiogenesis and vascular stability
It has been well documented that BM‐MSCs play a major role in angiogenesis and microvas‐
cularisation via promoting proliferation, migration and differentiation of microvascular
endothelial cells by producing basic FGF and VEGF‐A [146].
3.7. Requirements for the healing process
3.7.1. Infection fighting
Open wounds are at risk of infections by bacteria and other microorganisms causing serious
conditions such tetanus and gangrene and giving rise to chronic wounds, bone necrosis, long‐
term disabilities and death. Unfortunately, in some wound types, the necrotic tissues exudate
secretions which act as a medium for bacterial growth inside the wound and protect the
bacteria from the host's immune defence [147]. The use of disinfectant is useless, because they
damage the injured tissues and arrest wound contraction. Also, they are easily suppressed by
the inorganic substances present in the wound including blood components and other tissue
secretions [148]. Therefore, appropriate care is required to protect open wounds and reduce
the possibility of bacterial infection. Included in such cares are the treatments of wounds with
topical antibiotics to kill the invading bacteria and moisturise the wounded area [149, 150],
accelerate the healing process [151] and modulate inflammation [152]. Failure of antibiotic
treatment leads to non‐healing wounds in which bacteria thrive on dead tissue giving rise to
uncontrolled infection leading to additional complicated treatments including draining and
removal of dead tissues from the injured site or even amputation in the case of diabetic ulcers
[147, 150].
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3.7.2. Prevention of ischemia and hypoxia
Ischemia is defined as the failure of blood to reach the target tissue and characterised by
insufficient nutrient and oxygen supply resulting in turn in hypoxia and the insufficient
availability or very low oxygen concentration at the injury site [153]. Therefore, the prevention
of such circumstances is critical to the acceleration of wound‐healing process [154]. Cold
environment causes continuous constriction of blood vessels thereby reducing blood flow into
the injury site and causing ischemia. Therefore, keeping tissue warm will dilate blood vessels
facilitating blood flow and decrease the probability of ischemia initiation; however, hyper‐
thermia is not recommended as this increases the likelihood of post‐surgical infection [147]. In
some cases of diabetic ulcers and venous ulcers, surgery is required to treat ischemia by
revascularisation the veins and arteries to correct their function [155]. Another approaches to
combat ischemia include pressure‐assisted treatment or negative pressure wound therapy
(NPWT), involving the creation of a vacuum to drain and remove wound exudate and their
bacterial component, reducing tissue swelling, enhancing cell proliferation at the wounded
site and the production of extracellular matrix thereby improving the healing process [156,
157]. Hypoxemia could arise due to vascular disease that arrests oxygen transfer, high demand
for oxygen by tissue metabolism at the injured site and the formation of reactive oxygen species
(ROS) [153]. The best therapy for hypoxemia is increasing the oxygenation of injured tissue by
hyperbaric oxygen therapy (HBOT) to compensate oxygen limitations [155]. Also, higher
oxygen content results in bacterial death, the acceleration of growth factor production, the
enhancement of fibroblast growth and the promotion of angiogenesis [155, 157]. Another
method to treat hypoxemia is the use of antioxidants to reduce the presence of oxidant
substances [32].
MSCs could potentially be used to treat ischemia and hypoxia because they release angiogenic
and mitogenic factors such as VEGF, IGF‐1 and HGF which are well known to induce angio‐
genesis and myogenesis [158]. Intravenous (IV) administration of BM‐MSCs increased the
activity of matrix metalloproteinase‐2 and decreased the activity of matrix metalloproteinase‐
9 resulting in improved cardiac function in a rat model of diabetic cardiomyopathy [159]. Wang
et al. [160] showed that MSCs secrete hypoxia‐regulated haem oxygenase‐1, frizzled‐related
protein‐2, hypoxic Akt‐regulated stem cell factor, heat‐shock protein‐20, adrenomedullin (AM)
and SDF which collectively contribute to regeneration, neovascularisation and remodelling.
MSCs were also be used to treat diabetic limb ischemia in the ischemic hind limb of type II
diabetic mice due to the secretion of proangiogenic factors including hypoxia‐inducible factor
and VEGF, responsible for vasculogenesis, blood flow regulation [161] and improvement of
arterial perfusion in type 1 diabetic patients with gangrene [162]. A pilot study carried on
patients of critical limb ischemia, who did not respond to other therapies, showed that multiple
intramuscular injections of MSCs induced formation of vascular networks across the closed
arteries, resulting in successful improvement of limb ischemia in terms of pain reduction and
claudication [163]. In another study using a pig model of stenotic kidney blood flow, admin‐
istration of MSCs improved the architecture of microvessels in term of size and density [164].
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3.7.3. Regulation of growth factors and hormones
As previously described, growth mediatory factors play pivotal roles in wound healing.
Therefore, more quantities of these growth factors are required to progress the healing process,
in particular in case of chronic wounds, so they should be continuously upregulated [31, 32].
Several methodologies have been proposed to maintain efficient concentrations of growth
factors at the injury site. Direct application of such biomolecules, however, requires large
quantities and repetitive application. Spreading autologous platelets over the injury site which
later secrete growth factors such as EGF, IGF‐1, IGF‐2, TGF‐β and VEGF has been proposed
[165] as has the utilisation of keratinocytes and fibroblasts on a collagen matrix to enhance
further secretion of growth factors when applied on the wound [32, 166]. Another potential
way to protect efficient concentrations of growth factors at the wound site is through the
prevention of their breakdown by analytical enzymes and thereby preventing the formation
of proteases such as elastase [31, 32]. Oestrogen and prostaglandins have also been showed to
play a role in the healing process; maintenance of their concentration at efficient levels may
thus prevent excess neutrophils from reaching the injury site and produce more elastase [41,
49, 50, 167].
3.8. Limitations of using MSCs for wound healing
MSCs can be considered as a promising tool for treating non‐healing wounds; however, some
aspects of MSC biology need to be intensively studied before use in clinical application. One
of these is the problem of finding a source of MSC isolation with no invasive procedure for
autologous treatment, for example isolation of MSCs from peripheral blood instead of bone
marrow. Other questions include the following: What is the ideal number and timing of MSC
administration/implantation? How long can MSCs survive at the injury site after implantation?
Are multiple administrations or implantations required for successful healing? When do the
implanted MSCs start releasing their soluble secretions after implantation/administration?
And finally, are the secretions of MSCs controllable? Answers to these questions are important
and essential for the therapeutic use of MSCs and a safer and a more effective treatment for
non‐healing wounds.
4. Conclusion
Mesenchymal stem cells (MSCs) and their secretions are promising therapeutics for use in
accelerating wound healing. Ease of availability, isolation and in vitro expansion make MSCs
the best candidates for wound‐healing therapies in comparison with other stem cells including
embryonic stem cells (ESCs). Two main strategies could be used in the application of MSCs to
the treatment of non‐healing wounds. MSCs show the ability to differentiate into different cells
of the epidermis. Also, MSC secretions collected from their in vitro cultures (MSC‐CM) and
their small vesicles (MSC‐EXOSOME) are important for promoting proliferation and migration
of skin cells, such as keratinocytes and fibroblasts, into the injury site. MSC‐CM contains a
wide range of at least 36 known growth factors, and cytokines work in synergy to accelerate
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wound healing. These characteristics make MSCs unique when compared to other cells, such
as keratinocytes and fibroblasts, since keratinocytes are unable to migrate by themselves
without growth factors and cytokines and fibroblasts cannot differentiate into skin‐like cells.
Therefore, MSCs are bi‐functional combining wound healing and skin regeneration. MSC‐CM
and MSC‐EXOSOME if developed into a medicinal product could potentially be applied
directly onto the wounded area either by injection or by enriching biological dressings with
these growth factors and exosomes and aid in combating the problems of non‐healing wounds.
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